HIF-1α mRNA is not associated with histopathological regression following neoadjuvant chemoradiation in esophageal cancer

Anticancer Research

Volumn 26, Issue 6 B, 2006, Pages 4505-4509

  Ling, Frederike C ^a   Leimbach, Nadine ^a   Baldus, Stephan E ^a   Buechel, Sandra ^a   Neiss, Susanne ^a   Brabender, Jan ^a   Drebber, Uta ^a   Dienes, Hans P ^a   Mueller, Rolf P ^a   Hoelscher, Arnulf H ^a   Schneider, Paul M ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Esophageal adenocarcinoma; Esophageal squamous cell carcinoma; Histomorphological response; Hypoxia inducible factor 1 (HIF 1 ); Neoadjuvant treatment

Indexed keywords

BETA ACTIN; CISPLATIN; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; HIF1A PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS RESECTION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIATION DOSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; ESOPHAGUS TUMOR; GENETICS; MIDDLE AGED;

ADULT; AGED; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MIDDLE AGED; RNA, MESSENGER;

EID: 33845960697     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Sherman CA, Turrisi AT, Wallace MB and Reed CE: Locally advanced esophageal cancer. Curr Treat Options Oncol 3(6): 475-485, 2002.
2. Medical Research Council Oesophageal Cancer Working Group: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359: 1727-1733, 2002.
3. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A and Strawderman M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 79: 305-313, 2001.
4. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N and Hennessy TP: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335: 462-467, 1996.
5. Kelsen DP: Multimodality therapy of esophageal cancer: an update. Cancer J 6 Suppl 2: S177-S181, 2000.
6. Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E, Schaefer H, Thiele J, Dienes HP, Mueller RP and Hoelscher AH: Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 242(5): 684-692, 2005.
7. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
8. Hopfl G, Ogunshola O and Gassmann M: HIFs and tumors - causes and consequences. Am J Physiol Regul Integr Comp Physiol 286: R608-623, 2004.
9. Xi H, Baldus SE, Warnecke-Eberz U, Brabender J, Neiss S, Metzger R, Ling FC, Dienes HP, Bollschweiler E, Moenig S, Mueller RP, Hoelscher AH and Schneider PM: High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin Cancer Res 11(23): 8341-8347, 2005.
10. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 187-220, 1958.
11. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966.
12. Sohda M, Ishikawa H, Masuda N, Kato H, Miyazaki T, Nakajima M, Fukuchi M, Manda R, Fukai Y, Sakurai H and Kuwano H: Pretreatment evaluation of combined HIF-1α, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int J Cancer 110: 838-844, 2004.
13. Matsuyama T, Nakanishi K, Hayashi T, Yoshizumi Y, Aiko S, Sugiura Y, Tanimoto T, Uenoyama M, Ozeki Y and Maehara T: Expression of hypoxia-inducible factor-1α in esophageal squamous cell carcinoma. Cancer Sci 96: 176-182, 2005.
14. Kurokawa T, Miyamoto M, Kato K, Cho Y, Kawarada Y, Hida Y, Shinohara T, Itoh T, Okushiba S, Kondo S and Katoh H: Overexpression of hypoxia-inducible- factor 1α (HIF-1α) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. British J Cancer 89: 1042-1047, 2003.
15. Vordermark D and Brown JM: Endogenous markers of tumor hypoxia. Predictors of clinical radiation resistance? Strahlenther Oncol 179(12): 801-811, 2003.
16. Birner P, Schindl M, Obermair A, Breitenecker G and Oberhuber G: Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7: 1661-1668, 2001.
17. Haugland HK, Vukovic V, Pintilie M, Fyles AW, Milosevic M, Hill RP and Hedley DW: Expression of hypoxia-inducible factor-1alpha in cervical carcinomas: correlation with tumor oxygenation. Int J Radiat Oncol Biol Phys 53(4): 854-861, 2002.
18. Beasley NJ, Leek R, Alam M, Turley H, Cox GJ, Gatter K, Millard P, Fuggle S and Harris AL: Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 62(9): 2493-2497, 2002.
19. Volm M and Koomagi R: Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res 20: 1527-1533, 2000.
20. Stroka DM, Burkhardt T, Desbaillets I, Wenger RH, Neil DA, Bauer C, Gassmann M and Candinas D: HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J 15(13): 2445-2453, 2001.
21. Brabender J, Marjoram P, Salonga D, Metzger R, Schneider PM, Park JM, Schneider S, Hölscher AH, Yin J, Meltzer SJ, Danenberg KD, Danenberg PV and Lord RV: A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus. Oncogene 23: 4780-4788, 2004.
22. Brabender J, Marjoram P, Lord RV, Metzger R, Salonga D, Vallbohmer D, Schafer H, Danenberg KD, Danenberg PV, Selaru FM, Baldus SE, Holscher AH, Meltzer SJ and Schneider PM: The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma. Cancer Epidemiol Biomarkers Prev 14(9): 2113-2117, 2005.